Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Nucleic Acids Res ; 49(19): 11211-11223, 2021 11 08.
Artigo em Inglês | MEDLINE | ID: mdl-34614173

RESUMO

Binding and unbinding of transcription factors to DNA are kinetically controlled to regulate the transcriptional outcome. Control of the release of the transcription factor NF-κB from DNA is achieved through accelerated dissociation by the inhibitor protein IκBα. Using single-molecule FRET, we observed a continuum of conformations of NF-κB in free and DNA-bound states interconverting on the subseconds to minutes timescale, comparable to in vivo binding on the seconds timescale, suggesting that structural dynamics directly control binding kinetics. Much of the DNA-bound NF-κB is partially bound, allowing IκBα invasion to facilitate DNA dissociation. IκBα induces a locked conformation where the DNA-binding domains of NF-κB are too far apart to bind DNA, whereas a loss-of-function IκBα mutant retains the NF-κB conformational ensemble. Overall, our results suggest a novel mechanism with a continuum of binding modes for controlling association and dissociation of transcription factors.


Assuntos
DNA/genética , Interferons/genética , Inibidor de NF-kappaB alfa/genética , Fator de Transcrição RelA/genética , Transcrição Gênica , Animais , Avidina/química , Sítios de Ligação , Biotina/química , DNA/metabolismo , Transferência Ressonante de Energia de Fluorescência , Regulação da Expressão Gênica , Humanos , Proteínas Imobilizadas/química , Proteínas Imobilizadas/genética , Proteínas Imobilizadas/metabolismo , Interferons/química , Interferons/metabolismo , Sequências Repetidas Invertidas , Camundongos , Simulação de Dinâmica Molecular , Inibidor de NF-kappaB alfa/química , Inibidor de NF-kappaB alfa/metabolismo , Ligação Proteica , Conformação Proteica em alfa-Hélice , Conformação Proteica em Folha beta , Domínios e Motivos de Interação entre Proteínas , Imagem Individual de Molécula/métodos , Fator de Transcrição RelA/química , Fator de Transcrição RelA/metabolismo
2.
J Biochem Mol Toxicol ; 35(3): e22656, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33094891

RESUMO

Due to unavailability of a specific drug/vaccine to attenuate severe acute respiratory syndrome coronavirus 2, the current strategy to combat the infection has been largely dependent upon the use of anti-inflammatory drugs to control cytokines storm responsible for respiratory depression. Thus, in this study, we discovered novel pyrazole analogs as a potent nuclear factor kappa B (NF-ĸB) inhibitor. The compounds were assessed for NF-ĸB transcriptional inhibitory activity in RAW264.7 cells after stimulation with lipopolysaccharides (LPS), revealing Compound 6c as the most potent analog among the tested series. The effect of Compound 6c was further investigated on the levels of interleukin-1ß, tumor necrosis factor-α, and interleukin-6 in LPS-stimulated RAW267.4 cells by enzyme immunoassay, where it causes a significant reduction in the level of these cytokines. In Western blot analysis, Compound 6c also causes the inhibition of inhibitor kappa B-α and NF-κB. It was found to be snugly fitted into the inner grove of the active site of NF-ĸB by forming H-bonds and a nonbonded interaction with Asn28 in a docking analysis.


Assuntos
Anti-Inflamatórios , Tratamento Farmacológico da COVID-19 , COVID-19 , Simulação de Acoplamento Molecular , Inibidor de NF-kappaB alfa , NF-kappa B/metabolismo , Pirazóis , SARS-CoV-2/metabolismo , Transdução de Sinais/efeitos dos fármacos , Animais , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , COVID-19/metabolismo , COVID-19/patologia , Citocinas/metabolismo , Camundongos , Inibidor de NF-kappaB alfa/antagonistas & inibidores , Inibidor de NF-kappaB alfa/química , Inibidor de NF-kappaB alfa/metabolismo , Pirazóis/química , Pirazóis/farmacologia , Células RAW 264.7
3.
J Nat Prod ; 82(6): 1434-1441, 2019 06 28.
Artigo em Inglês | MEDLINE | ID: mdl-31181925

RESUMO

Four new hybrid peptide-polyketide cyclic tridepsipeptides, colletopeptides A-D (1-4), were isolated and characterized from the endophytic fungus Colletotrichum sp. S8 derived from the stems of Rubia podantha with the guidance of LC-UV-MS detection. Their structures were elucidated by extensive spectroscopic analysis and X-ray crystallography. Compounds 1-4 are rare natural 12-membered cyclic tridepsipeptides containing a 3,5,11-trihydroxy-2-methyl dodecanoic acid unit in their structures. 1-4 inhibited lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages with the IC50 values of 8.3, 38.7, 13.5, and 22.2 µM, respectively. 1 also inhibited the production of inflammatory factors IL-6 and TNF-α, and decreased the phosphorylation of NF-κB-associated proteins IκBα and p65.


Assuntos
Anti-Inflamatórios/farmacologia , Colletotrichum/química , Depsipeptídeos/farmacologia , Lipopolissacarídeos/farmacologia , Macrófagos/química , Inibidor de NF-kappaB alfa/metabolismo , NF-kappa B/química , Óxido Nítrico/biossíntese , Fator de Necrose Tumoral alfa/química , Anti-Inflamatórios/química , Depsipeptídeos/química , Depsipeptídeos/isolamento & purificação , Lipopolissacarídeos/química , Macrófagos/metabolismo , Estrutura Molecular , Inibidor de NF-kappaB alfa/química , NF-kappa B/metabolismo , Fosforilação , Fator de Necrose Tumoral alfa/metabolismo
4.
Biochemistry ; 58(21): 2555-2563, 2019 05 28.
Artigo em Inglês | MEDLINE | ID: mdl-31033276

RESUMO

The NFκB transcription factor family members RelA, p50, and cRel form homo- and heterodimers that are inhibited by IκBα, IκBß, and IκBε. These NFκB family members have diverse biological functions, and their expression profiles differ, leading to different concentrations in different tissue types. Here we present definitive biophysical measurements of the NFκB dimer affinities and inhibitor affinities to better understand dimer exchange and how the presence of inhibitors may alter the equilibrium concentrations of NFκB dimers in the cellular context. Fluorescence anisotropy binding experiments were performed at low concentrations to mimic intracellular concentrations. We report binding affinities much stronger than those that had been previously reported by non-equilibrium gel shift and analytical ultracentrifugation assays. The results reveal a wide range of NFκB dimer affinities and a strong preference of each IκB for a small subset of NFκB dimers. Once the preferred IκB is bound, dimer exchange no longer occurs over a period of days. A mathematical model of the cellular distribution of these canonical NFκB transcription factors based on the revised binding affinities recapitulates intracellular observations and provides simple, precise explanations for observed cellular phenomena.


Assuntos
Inibidor de NF-kappaB alfa/química , Subunidade p50 de NF-kappa B/química , Multimerização Proteica , Fator de Transcrição RelA/química , Animais , Citoplasma/metabolismo , Fibroblastos/metabolismo , Polarização de Fluorescência , Meia-Vida , Camundongos , Modelos Teóricos , Ligação Proteica , Proteólise , Fator de Transcrição RelA/antagonistas & inibidores
5.
J Mol Graph Model ; 86: 264-277, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30415122

RESUMO

Nuclear factor-κB (NF-κB) transcription factors represent a conserved family of proteins that regulate not only immune cells, but also heart cells, glial cells and neurons, playing a fundamental role in various cellular processes. Due to its dysregulation in certain cancer types as well as in chronic inflammation and autoimmune diseases, it has recently been appreciated as an important therapeutic target. The aim of this study was to investigate the binding pocket of NF-κB (p50/p65) heterodimer complex in association with NF-κB inhibitor IκBα to identify potent ligands via fragment-based e-pharmacophore screening. The ZINC Clean Fragments (∼2 million) and the Schrodinger's medically relevant Glide fragments library (∼670) were used to create the e-pharmacophore models at the potential binding site which was validated by site mapping. Glide/HTVS docking was conducted followed by re-docking of the top 20% fragments by Glide/SP and Glide/XP protocols. The top-85000 Glide XP-docked fragments were used to generate the e-pharmacophore hypotheses. The Otava small molecule library (∼260000 drug-like molecules) and 85 known NF-κB inhibitors were additionally screened against the derived e-pharmacophore models. The top-1000 high-scored molecules, which were well aligned to the e-pharmacophore models, from the Otava small molecule library, were then docked into the binding pocket. Finally, the selected 88 hit molecules and the 85 known inhibitors were analyzed by the MetaCore/MetaDrug™ platform, which uses developed binary QSAR models for therapeutic activity prediction as well as pharmacokinetic and toxicity profile predictions of screening molecules. Ligand selection criteria led to the refinement of 3 potent hit molecules using molecular dynamics (MD) simulations to better investigate their structural and dynamical profiles. The selected hit molecules had a low toxicity and a significant therapeutic potential for heart failure, antiviral activity, asthma and depression, all conditions in which NF-κB plays a critical role. These hit ligands were also structurally stable at the NF-κB/IκBα complex as per the MD simulations and MM/GBSA analysis. Two of these ligands (Otava IDs: 1426436 and 6248112) showed stronger binding and therefore are hypothesized to be more potent. The identification of new potent NF-κB/IκBα inhibitors may thus present a novel therapy for inflammation-mediated conditions as well as cancer, facilitating more efficient research, and leading the way to future drug development efforts.


Assuntos
Desenho de Fármacos , Inibidor de NF-kappaB alfa/química , NF-kappa B/química , Relação Quantitativa Estrutura-Atividade , Sítios de Ligação , Biologia Computacional , Ligantes , Simulação de Acoplamento Molecular , Simulação de Dinâmica Molecular , Inibidor de NF-kappaB alfa/metabolismo , NF-kappa B/metabolismo , Ligação Proteica , Conformação Proteica
6.
Biomolecules ; 8(4)2018 10 05.
Artigo em Inglês | MEDLINE | ID: mdl-30301161

RESUMO

The proteasome is an intracellular complex that degrades damaged or unfolded proteins and participates in the regulation of several processes. The immunoproteasome is a specialized form that is expressed in response to proinflammatory signals and is particularly abundant in immune cells. In a previous work, we found an anti-inflammatory effect in a diterpenoid extracted from the octocoral Pseudopterogorgia acerosa, here called compound 1. This compound prevented the degradation of inhibitor κB α (IκBα) and the subsequent activation of nuclear factor κB (NFκB), suggesting that this effect might be due to inhibition of the ubiquitin-proteasome system. Here we show that compound 1 inhibits the proteasomal chymotrypsin-like activity (CTL) of murine macrophages in the presence of lipopolysaccharide (LPS) but not in its absence. This effect might be due to the capacity of this compound to inhibit the activity of purified immunoproteasome. The compound inhibits the cell surface expression of major histocompatibility complex (MHC)-I molecules and the production of proinflammatory cytokines induced by LPS in vitro and in vivo, respectively. Molecular docking simulations predicted that compound 1 selectively binds to the catalytic site of immunoproteasome subunits ß1i and ß5i, which are responsible for the CTL activity. Taken together these findings suggest that the compound could be a selective inhibitor of the immunoproteasome, and hence could pave the way for its future evaluation as a candidate for the treatment of inflammatory disorders and autoimmune diseases.


Assuntos
Diterpenos/farmacologia , Lipopolissacarídeos/farmacologia , Macrófagos/efeitos dos fármacos , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Animais , Quimases/química , Quimases/genética , Humanos , Macrófagos/imunologia , Complexo Principal de Histocompatibilidade/efeitos dos fármacos , Complexo Principal de Histocompatibilidade/imunologia , Camundongos , Simulação de Acoplamento Molecular , Inibidor de NF-kappaB alfa/química , Inibidor de NF-kappaB alfa/genética , NF-kappa B/química , Complexo de Endopeptidases do Proteassoma/química , Complexo de Endopeptidases do Proteassoma/imunologia
7.
J Antibiot (Tokyo) ; 70(9): 929-936, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28676715

RESUMO

Allantopyrone A is a fungal metabolite that uniquely possesses two α,ß-unsaturated carbonyl moieties. We recently reported that allantopyrone A inhibited the nuclear factor-κB (NF-κB) signaling pathway induced by tumor necrosis factor (TNF)-α in human lung carcinoma A549 cells. In the present study, the mechanism by which allantopyrone A inhibits the TNF-α-induced signaling pathway was investigated in more detail. Allantopyrone A blocked extensive modifications to receptor-interacting protein 1 (RIP1) in the TNF receptor 1 (TNF-R1) complex. Allantopyrone A augmented the high-MW bands of TNF-R1, TNF receptor-associated factor 2, RIP1, the NF-κB subunit RelA and inhibitor of NF-κB kinase ß in A549 cells, suggesting that it binds to and promotes the crosslinking of these proteins. The extracellular cysteine-rich domains of TNF-R1 were crosslinked by allantopyrone A more preferentially than its intracellular portion. The present results demonstrate that allantopyrone A interferes with multiple components of the TNF-R1 complex and blocks RIP1 modifications in the TNF-α-induced NF-κB signaling pathway.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Proteínas de Choque Térmico HSP90/antagonistas & inibidores , Pironas/farmacologia , Proteína Serina-Treonina Quinases de Interação com Receptores/antagonistas & inibidores , Receptores Tipo I de Fatores de Necrose Tumoral/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Células A549 , Cisteína/química , Cisteína/metabolismo , Genes Reporter/efeitos dos fármacos , Células HEK293 , Proteínas de Choque Térmico HSP90/química , Proteínas de Choque Térmico HSP90/genética , Proteínas de Choque Térmico HSP90/metabolismo , Humanos , Peso Molecular , Inibidor de NF-kappaB alfa/antagonistas & inibidores , Inibidor de NF-kappaB alfa/química , Inibidor de NF-kappaB alfa/metabolismo , Fragmentos de Peptídeos/antagonistas & inibidores , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/metabolismo , Domínios e Motivos de Interação entre Proteínas , Multimerização Proteica/efeitos dos fármacos , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Proteína Serina-Treonina Quinases de Interação com Receptores/química , Proteína Serina-Treonina Quinases de Interação com Receptores/genética , Proteína Serina-Treonina Quinases de Interação com Receptores/metabolismo , Receptores Tipo I de Fatores de Necrose Tumoral/química , Receptores Tipo I de Fatores de Necrose Tumoral/genética , Receptores Tipo I de Fatores de Necrose Tumoral/metabolismo , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Fator 2 Associado a Receptor de TNF/antagonistas & inibidores , Fator 2 Associado a Receptor de TNF/química , Fator 2 Associado a Receptor de TNF/metabolismo , Fator de Transcrição RelA/antagonistas & inibidores , Fator de Transcrição RelA/química , Fator de Transcrição RelA/metabolismo , Fator de Necrose Tumoral alfa/química , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo
8.
Proteins ; 85(1): 17-29, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-27701768

RESUMO

Activation of the transcription factor NF-κB requires degradation of its physiological inhibitor IκBα in order to allow nuclear translocation of NF-κB. NF-κB activity links inflammation and carcinogenesis and makes its signaling pathway an important target for therapeutic intervention. The signal-receiving N-terminal domain (SRD) of the NF-κB inhibitor IκBα harbors the sites of post-translational modifications (Ser32 and 36) directed by the IκB kinase (IKK) complex. The SRD was originally recognized to be highly disordered, but was recently shown to possess stable secondary structural elements. Identifying and characterizing the structural effects that arise from phosphorylation may explain how phosphorylation regulates the IκBα-NF-κB protein complex. Therefore, the effect of post-translational mono- and double-phosphorylation of the serine residues of the SRD was analyzed. The structural modifications of the IκBα-NF-κB protein-protein complex due to mono-phosphorylation of either Ser32 or Ser36 amino acid residues or simultaneous phosphorylation were investigated by means of molecular dynamics simulations. Mono-phosphorylation at either Ser32 or Ser36 was not sufficient to induce significant structural changes in the secondary structure of the SRD of IκBα. Double-phosphorylation yielded an increase in distance between the Cα atoms of these serine residues, indicative of a structural change. Only this two-fold phosphorylation induced the extended, more stabilized conformation of the degron motif which renders it accessible by the E3 ligase. In summary, these results provide insight into the conformational changes induced in IκBα proteins upon phosphorylation that are vital to their signaling dynamics and enable us to propose a model for the phosphorylation of the SRD. Proteins 2016; 85:17-29. © 2016 Wiley Periodicals, Inc.


Assuntos
Simulação de Dinâmica Molecular , Inibidor de NF-kappaB alfa/química , NF-kappa B/química , Processamento de Proteína Pós-Traducional , Serina/química , Sequência de Aminoácidos , Sítios de Ligação , Humanos , Inibidor de NF-kappaB alfa/metabolismo , NF-kappa B/metabolismo , Fosforilação , Ligação Proteica , Conformação Proteica em alfa-Hélice , Conformação Proteica em Folha beta , Domínios e Motivos de Interação entre Proteínas , Proteólise , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , Serina/metabolismo , Transdução de Sinais
9.
Sci Rep ; 6: 26554, 2016 05 23.
Artigo em Inglês | MEDLINE | ID: mdl-27212040

RESUMO

Adhesion molecules expressed on cerebral endothelial cells (ECs) mediate leukocyte recruitment and play a significant role in cerebral inflammation. Increased levels of adhesion molecules on the EC surface induce leukocyte infiltration into inflammatory areas and are thus hallmarkers of inflammation. Honokiol, isolated from the Chinese medicinal herb Magnolia officinalis, has various pharmacological activities, including anti-inflammatory effects, yet the nature of honokiol targeting molecules remains to be revealed. Here, we investigated the inhibitory effect of honokiol on neutrophil adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression, which underlie its molecular target, and mechanisms for inactivating nuclear factor κ enhancer binding protein (NF-κB) in mouse cerebral ECs. Honokiol inhibited tumour necrosis factor-α (TNF-α)-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs. The inflammatory transcription factor NF-κB was downregulated by honokiol. Honokiol significantly blocked TNF-α-induced NF-κB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-κB α (IκBα). From docking model prediction, honokiol directly targeted the ubiquitin-ubiquitin interface of Lys48-linked polychains. Moreover, honokiol prevented the TNF-α-induced Lys48-linked polyubiquitination, including IκBα-polyubiquitin interaction. Honokiol has protective anti-inflammatory effects on TNF-α-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs, at least in part by directly inhibiting ubiquitination-mediated IκBα degradation and then preventing NF-κB nuclear translocation.


Assuntos
Compostos de Bifenilo/farmacologia , Encéfalo/citologia , Lignanas/farmacologia , Inibidor de NF-kappaB alfa/metabolismo , Neutrófilos/citologia , Fator de Necrose Tumoral alfa/metabolismo , Animais , Adesão Celular/efeitos dos fármacos , Células Cultivadas , Células Endoteliais/citologia , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Camundongos , Inibidor de NF-kappaB alfa/química , Neutrófilos/efeitos dos fármacos , Proteólise/efeitos dos fármacos , Ubiquitinação/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/metabolismo
10.
Protein Sci ; 25(3): 597-604, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26647230

RESUMO

NF-κB is a major transcription factor that mediates a number of cellular signaling pathways. Crystal structure analysis gives an incomplete picture of the behavior of the protein, particularly in the free state; free monomers or dimers of NF-κB have never been crystallized. NMR analysis gives insights into the structure and dynamics of the protein in solution, but a necessary first step is the assignment of resonances. The size of the heterodimer of the Rel homology regions of the NF-κB monomers p65 and p50 (72 kDa) prohibits the straightforward use of triple-resonance spectroscopy to obtain the assignments. However, the dynamic nature of the free heterodimer, in particular the independence of the DNA-binding and dimerization domains of each monomer, allows the assignments made on differentially labeled smaller domains to be mapped successfully onto the spectrum of the larger full-length RHR. Problematic areas such as the p65 nuclear localization sequence, which is disordered in the free protein, can be approached by residue-specific labeling and comparison with previously-published spectra of a short peptide with the same sequence. Overall, this NMR analysis of NF-κB has given valuable insights into the highly dynamic nature of the free state, which is likely to play an important role in the functional cycle of NF-κB in the cell.


Assuntos
Subunidade p50 de NF-kappa B/química , Fator de Transcrição RelA/química , Animais , DNA/metabolismo , Camundongos , Simulação de Dinâmica Molecular , Inibidor de NF-kappaB alfa/química , Inibidor de NF-kappaB alfa/metabolismo , Subunidade p50 de NF-kappa B/metabolismo , Ressonância Magnética Nuclear Biomolecular , Conformação Proteica , Domínios Proteicos , Multimerização Proteica , Fator de Transcrição RelA/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA